In sudden revamp, Celgene CEO Alles bids his COO goodbye and looks to regain confidence with management shuffle
Staggered by a series of late-stage setbacks capped by the FDA’s refusal to accept its application on their leading late-stage drug and looking vulnerable on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
